A Phase 1 Single- and Multiple-ascending-dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of S-740792 in Healthy Adult Study Participants
Latest Information Update: 11 Jun 2025
At a glance
- Drugs S 740792 (Primary) ; Midazolam
- Indications Neurologic gait disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shionogi
Most Recent Events
- 04 Jun 2025 Trial amended with addition of open label part 3 (bioavailability) arm. Primary endpoints related to pharmacokinetics added newly.
- 04 Jun 2025 Planned number of patients changed from 116 to 131.
- 17 Dec 2024 New trial record